Publications by authors named "James E Ray"

Claim this Profile
C
Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.
Jian Liang, Richard E Moore, Eric D Moher, John E Munroe, Rima S Al-awar, James E Ray

Invest New Drugs· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological evaluation of cryptophycin 52 fragment A analogues: effect of the multidrug resistance ATP binding cassette transporters on antitumor activity.
Rima S Al-Awar, Thomas H Corbett, James E Ray, Lisa Polin, Joseph H Kennedy

Mol Cancer Ther· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.
Rima S Al-awar, James E Ray, Kyle A Hecker, Sajan Joseph, Jianping Huang

Bioorg Med Chem Lett· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.
Rima S Al-awar, James E Ray, Kyle A Hecker, Jianping Huang, Philip P Waid

Bioorg Med Chem Lett· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.
Margaret M Faul, Thomas A Engler, Kevin A Sullivan, John L Grutsch, Marcella T Clayton, James E Ray

J Org Chem· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.
Rima S Al-Awar, James E Ray, Richard M Schultz, Sherri L Andis, Joseph H Kennedy

J Med Chem· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis